Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics Previous close 50.98
Open 49.95
Day range 49.15 50.12
52-week range 42.77 61.40
Off day high −1.94%
Off 52-week high −19.95%
Volume 0.00
Avg. volume (3M) 125
Market cap 9.51B
EPS (TTM) 0.3200
Forward P/E —
P/E ratio (TTM) 153.59
Dividend yield —
Beta (5Y) —
Shares outstanding 193.57M
Short interest —
Earnings date Aug 6, 2026 (est.)
Analyst target —
Profit margin —
No recent coverage in the 4Search index.
From articles in the 4Search news index.
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
From Wikipedia , CC BY-SA 4.0
Earnings
Next report: Thu, Aug 6, 2026 (estimated)
Not eligible for Gainers, Losers, Most active (U.S. stocks worth $2 billion or more only).
Not eligible for Small-cap gainers, Aggressive small caps (U.S. stocks worth under $2 billion only).
Not eligible for Growth tech (U.S. technology stocks only).
Not eligible for Undervalued large caps (U.S. stocks worth $10 billion or more only).
A day counts when it ranked in the top 25 of a list. Tracked since Oct 10, 2026.
Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use .